Axiara Therapeutics is a discovery-stage CNS drug discovery company building a pipeline of first-in-class, small-molecule medicines for conditions where existing therapies fall short and the underlying circuit dysfunction goes unaddressed.
Every program begins with mechanistic insight, how small molecules engage a specific binding site, how that engagement translates to functional modulation, and how it maps to disease-relevant circuits.
Medicinal chemistry guided by structural and functional data. Compound design is informed by direct knowledge of target pharmacology, binding-site architecture, and selectivity, not empirical screening.
Exclusive licenses to intellectual property from leading research universities, backed by a network spanning electrophysiology, structural pharmacology, computational chemistry, and in vivo pharmacology.
Spanning multiple therapeutic areas and stages of discovery, each advancing scientifically validated biology toward optimized, proprietary development candidates.
Programs built around targets where the team has direct, molecular-level knowledge of engagement, selectivity across subtypes, and therapeutic effect in disease models. A rare foundation and a real competitive edge.
Every program is supported by published, peer-reviewed data demonstrating target relevance in disease, replicated across independent groups in cellular and in vivo models. Not a bet on unvalidated biology.
Deep drug-discovery expertise paired with experienced biotech and translational leadership. A lean structure, licensed IP, and existing data package direct capital straight into program advancement.
Programs grounded in peer-reviewed research published in leading journals, with founders and collaborators who characterized the molecular pharmacology and therapeutic relevance of the target class.
Axiara Therapeutics · Cambridge, Massachusetts
GET IN TOUCH · info@axiaratx.com